Active, not recruitingPhase 3NCT07047521

A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults

Studying Dengue fever

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Takeda
Principal Investigator: Study Director
Takeda
Intervention: Tetravalent Dengue Vaccine (TDV)(biological)
Enrollment: 496 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2025 – 2027

Study locations (5)

Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia
Emeritus Research Sydney, Botany, New South Wales, Australia
Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia
Veritus Research, Bayswater, Victoria, Australia
Emeritus Research Camberwell (Melbourne), Camberwell, Victoria, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07047521 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials